ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025
Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy.
Abstract read
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment.European journal of nuclear medicine and molecular imaging · 2026Article
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- Tau-mediated Mechanisms in Alzheimer's Disease Pathogenesis.Molecular neurobiology · 2026Review
- MR-Guided PET Denoising and Resolution Enhancement Improves Visual Interpretation and Preserves Quantitative Behavior Across Amyloid Tracers.medRxiv : the preprint server for health sciences · 2026Article
- The prognostic value of blood-based p-tau217 levels on progression to clinical impairment.medRxiv : the preprint server for health sciences · 2026Article
- Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Features predicting data exclusion in imaging studies of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Jiaxiuxiu ZhangMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
David N Soleimani-MeigooniMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Robert KoeppeUniversity of Michigan, Ann Arbor, Michigan.
Sarah AckleyDepartment of Epidemiology, Brown University, Providence, Rhode Island.
Daniel R SchonhautMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Zoe E LinMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Piyush MaitiMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Claire YballaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Salma RochaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Ranjani ShankarMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Alinda AmuiriMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Pierrick BourgeatCSIRO Health and Biosecurity, Brisbane, Queensland, Australia.
Vincent DoréCSIRO Health and Biosecurity, Brisbane, Queensland, Australia.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois.
Bradford C DickersonMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Liana G ApostolovaIndiana University School of Medicine, Indianapolis, Indiana.
Theresa M HarrisonNeuroscience Department, University of California, Berkeley, Berkeley, California; and.
Lea T GrinbergMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Salvatore SpinaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
William W SeeleyMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Renaud La JoieMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California.
Ganna Blazhenets
LEADS Consortium and Alzheimer’s Disease Neuroimaging Initiative
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MEarly Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5MResearch Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1MResearch Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3MThe Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2020 to 2026
$29.0MStanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Lisa Goldman Rosas · 2020 to 2026
$29.0MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7MNIA NIH HHS K01 AG078443NIA NIH HHS K23 AG076960NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS P50 AG023501NIA NIH HHS R00 AG073454NIA NIH HHS R01 AG034570NIA NIH HHS R01 AG061111NIA NIH HHS R35 AG072362NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG024904NIA NIH HHS U24 AG021886
Abstract
As Centiloids are increasingly used in trials and clinical settings to quantify amyloid-β (Aβ) PET, better characterization of sources of measurement error is essential. We examined 2 potential factors driving it: variability in the estimated coefficients in the SUV ratio-to-Centiloid conversion equation related to random sampling of the calibration dataset and PET image resolution.
Indexed as
Image Processing, Computer-AssistedPositron-Emission TomographyAgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedSample SizeThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsThiazolesamyloid PETCentiloidneurologyPET quantification
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.